mBeach said that completing the regulatory procedures will pave the way for local clinical trials and a full commercial launch of SkinScan 650, Skin Cancer Scanning’s (SCS) non-invasive, point-of-care system to detect and identify different types of skin cancers. SCS expects to receive the initial import approval by the end of October 2010.

Yossi Biderman, CEO of mBeach, said: “We are excited at the prospects of entering this very large and attractive region, one of the fastest-growing healthcare markets in the world. Typically in Russia today, cancer is diagnosed at relatively advanced stages when treatment options are less effective and more costly.

“Our market research identifies a clear demand for advanced medical technologies such as ours for the early detection of skin cancer. We will be working closely with our local distributor and look forward to updating our shareholders on our progress in this important market.”

SCS is a medical device company which develops the imaging system for the early detection and diagnosis of skin cancer.